RA PHARMACEUTICALS INC's ticker is RARX and the CUSIP is 74933V108. A total of 59 filers reported holding RA PHARMACEUTICALS INC in Q4 2016. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $35,198,000 | +78.2% | 750,000 | -10.2% | 1.11% | +41.3% |
| Q3 2019 | $19,748,000 | -18.3% | 835,000 | +3.9% | 0.79% | -10.1% |
| Q2 2019 | $24,176,000 | +34.2% | 804,000 | 0.0% | 0.88% | +26.1% |
| Q1 2019 | $18,010,000 | +31.9% | 804,000 | +7.2% | 0.69% | +7.8% |
| Q4 2018 | $13,650,000 | +0.6% | 750,000 | 0.0% | 0.64% | +31.2% |
| Q3 2018 | $13,568,000 | +81.8% | 750,000 | 0.0% | 0.49% | +71.1% |
| Q2 2018 | $7,463,000 | +134.2% | 750,000 | +25.0% | 0.29% | +111.0% |
| Q1 2018 | $3,186,000 | -37.5% | 600,000 | 0.0% | 0.14% | -41.1% |
| Q4 2017 | $5,100,000 | -41.8% | 600,000 | 0.0% | 0.23% | -42.8% |
| Q3 2017 | $8,760,000 | -22.1% | 600,000 | 0.0% | 0.40% | -28.9% |
| Q2 2017 | $11,244,000 | -33.1% | 600,000 | -24.0% | 0.57% | -41.4% |
| Q1 2017 | $16,797,000 | +33.9% | 788,959 | -4.5% | 0.97% | +15.4% |
| Q4 2016 | $12,547,000 | – | 826,000 | – | 0.84% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 3,851,808 | $20,453,000 | 1.57% |
| NEA Management Company, LLC | 5,493,636 | $29,171,000 | 1.30% |
| Foresite Capital Management IV, LLC | 450,000 | $2,390,000 | 0.99% |
| Novo Holdings A/S | 1,465,838 | $7,784,000 | 0.98% |
| Consonance Capital Management LP | 1,454,761 | $7,725,000 | 0.71% |
| VHCP Management II, LLC | 544,612 | $2,892,000 | 0.70% |
| ACUTA CAPITAL PARTNERS, LLC | 270,000 | $1,434,000 | 0.23% |
| Athanor Capital, LP | 67,150 | $357,000 | 0.16% |
| Rock Springs Capital Management LP | 600,000 | $3,186,000 | 0.14% |
| Eventide Asset Management | 388,000 | $2,060,000 | 0.10% |